Oncogenes play a key role in the development of cancers. One of the most commonly mutated oncogenes in cancer is PI3Ka. It is found in approximately 13% of human cancers and 29% of breast cancer. There are three most common mutations of PI3Ka namely H1047R, E542K, and E545K. The approved PI3Ka inhibitors that are on the market are associated with significant on-target toxicities, including hyperglycemia, rash, fatigue, and diarrhea.
The company we are profiling today is OnKure Therapeutics Inc. (OKUR), which is developing a drug by the name OKI-219 that targets the PI3KaH1047R mutation.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.